Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Polen Capital - International Growth 2023 Q3 Investor Letter | Buyside Digest

Back to Fund Profile (Polen Capital - International Growth)

Primary Source Intelligence • Q3 2023 Letter Analysis

Polen Capital - International Growth Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Polen Capital - International Growth. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

Annualized+4.76%

Digest Analysis

Quick Take

"Polen Capital's International Growth strategy underperformed in Q3 but maintains strong YTD outperformance. The team sees opportunity in historically cheap international valuations and quality's rare underperformance, adding Novo Nordisk for GLP-1 exposure while trimming CSL."

Executive Summary

Polen Capital's International Growth strategy declined 7.80% net in Q3 2023, underperforming the MSCI ACWI ex-USA Index's -3.77% return, though maintaining strong year-to-date outperformance at 10.85% versus 5.35%. The managers emphasize that non-US equity valuations have rarely been this cheap relative to the US in nearly two decades, while quality companies have historically outperformed in 18 of the past 24 years. Top contributors included Sage Group, MercadoLibre, and Globant, while Evolution AB, Teleperformance, and Amadeus detracted. Portfolio activity included initiating a position in Novo Nordisk, capitalizing on the GLP-1 drug opportunity with an estimated $200B+ global addressable market, while trimming CSL to fund the purchase. The managers view the current environment as opportune for quality investing in international markets, combining low starting valuations with quality's rare underperformance setting up potential mean reversion. They expect their concentrated portfolio of quality companies to deliver above-index growth rates over the coming five years despite current macro headwinds.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

The managers demonstrate moderate-high conviction through detailed analysis of individual holdings, specific position sizing decisions (initiating Novo Nordisk, trimming CSL), and clear thesis articulation. However, the diversified nature of the portfolio and acknowledgment of multiple scenarios prevents a higher score. The extensive commentary on specific companies and willingness to make concentrated bets supports this level.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The managers acknowledge slowing growth prospects and macro headwinds but frame cheap international valuations as a positive attribute. They express optimism about quality's future outperformance based on historical patterns, balancing caution about current conditions with constructive long-term views.

Risk Appetite

15%

DefensiveAggressive

Defensive (15%)

The portfolio shows selective risk-taking through the new Novo Nordisk position while trimming CSL, indicating measured deployment rather than aggressive risk-on positioning. The managers maintain conviction in existing holdings despite underperformance, suggesting a cautious but committed stance.

Capital Deployment

15%

De-riskingDeploying

De-risking (15%)

Portfolio activity was limited to one new position (Novo Nordisk) funded by trimming an existing holding (CSL), representing rotation rather than net deployment. No cash level changes were mentioned, and the managers describe selective rather than aggressive deployment, indicating modest positive activity.

Forward Guidance

30%

CautiousExpansionary

Cautious (30%)

The managers express confidence in their portfolio's positioning for future outperformance and expect quality to be rewarded again. They indicate readiness to capitalize on opportunities while maintaining their quality-focused approach, showing mild deployment bias toward their investment thesis.

Language Signal

20%

BearishBullish

Bearish (20%)

Language includes positive terms like 'opportune time,' 'compelling,' and 'attractive' balanced against risk language around 'concerns,' 'headwinds,' and 'challenging environments.' The net balance tilts slightly positive with opportunity-focused framing dominating the narrative.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

The managers acknowledge moderate risks including slow growth prospects, business expansion limitations, and macro headwinds from rate hikes and economic normalization. However, risks are discussed as manageable challenges rather than systemic threats, with emphasis on quality companies' ability to navigate difficult environments.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

The managers see selective opportunities, particularly in quality international companies trading at historically cheap valuations. They identify specific attractive investments like Novo Nordisk while maintaining conviction in existing holdings, suggesting a moderately rich opportunity set within their quality framework.

Time Horizon

75%

Short-TermLong-Term

Decade+ (75%)

The managers explicitly discuss five-year earnings growth prospects and reference historical patterns spanning decades. They emphasize long-term compounding and quality's historical outperformance over 24 years, indicating a multi-year investment horizon with patience for thesis realization despite near-term volatility.